These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1404 related items for PubMed ID: 11443153

  • 1. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
    Kamp GA, Mul D, Waelkens JJ, Jansen M, Delemarre-van de Waal HA, Verhoeven-Wind L, Frölich M, Oostdijk W, Wit JM.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
    [Abstract] [Full Text] [Related]

  • 2. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone.
    Pasquino AM, Pucarelli I, Roggini M, Segni M.
    J Clin Endocrinol Metab; 2000 Feb; 85(2):619-22. PubMed ID: 10690865
    [Abstract] [Full Text] [Related]

  • 3. The effect of administering gonadotropin-releasing hormone agonist with recombinant-human growth hormone (GH) on the final height of girls with isolated GH deficiency: results from a controlled study.
    Saggese G, Federico G, Barsanti S, Fiore L.
    J Clin Endocrinol Metab; 2001 May; 86(5):1900-4. PubMed ID: 11344181
    [Abstract] [Full Text] [Related]

  • 4. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F.
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [Abstract] [Full Text] [Related]

  • 5. GH and GnRH analog treatment in children who enter puberty at short stature.
    Tanaka T, Satoh M, Yasunaga T, Horikawa R, Tanae A, Hibi I.
    J Pediatr Endocrinol Metab; 1997 Feb; 10(6):623-8. PubMed ID: 9467133
    [Abstract] [Full Text] [Related]

  • 6. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
    Pasquino AM, Municchi G, Pucarelli I, Segni M, Mancini MA, Troiani S.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):948-51. PubMed ID: 8772556
    [Abstract] [Full Text] [Related]

  • 7. Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: results of a prospective, randomized trial.
    Mericq MV, Eggers M, Avila A, Cutler GB, Cassorla F.
    J Clin Endocrinol Metab; 2000 Feb; 85(2):569-73. PubMed ID: 10690857
    [Abstract] [Full Text] [Related]

  • 8. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia.
    Quintos JB, Vogiatzi MG, Harbison MD, New MI.
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1511-7. PubMed ID: 11297576
    [Abstract] [Full Text] [Related]

  • 9. Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty.
    van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJ, Jansen M, Verhoeven-Wind L, Delemarre-van de Waal HA, de Muinck Keizer-Schrama SM, Leusink G, Roos JC, Wit JM.
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1402-8. PubMed ID: 17284626
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial.
    Lem AJ, van der Kaay DC, de Ridder MA, Bakker-van Waarde WM, van der Hulst FJ, Mulder JC, Noordam C, Odink RJ, Oostdijk W, Schroor EJ, Sulkers EJ, Westerlaken C, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4096-105. PubMed ID: 22904179
    [Abstract] [Full Text] [Related]

  • 19. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
    de Zegher F, Du Caju MV, Heinrichs C, Maes M, De Schepper J, Craen M, Vanweser K, Malvaux P, Rosenfeld RG.
    J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
    [Abstract] [Full Text] [Related]

  • 20. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment.
    Fjellestad-Paulsen A, Simon D, Czernichow P.
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1234-9. PubMed ID: 15001616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.